Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.60 |
| ▸ | PPARG | P37231 | 11/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE8B | O95263 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867551 | 0.92 | ALDH1A1 (0.56) | PPARAPPARGKDM4EALDH1A1LMNA | |
| SCHEMBL1872432 | 0.91 | PPARA (0.49) | PPARAPPARGKDM4EALDH1A1LMNA | |
| SCHEMBL12802902 | 0.91 | PPARA (0.61) | PPARAPPARGKDM4EALDH1A1LMNA | |
| SCHEMBL1863168 | 0.90 | PPARA (0.64) | PPARAPPARGKDM4EALDH1A1LMNA | |
| SCHEMBL1878175 | 0.90 | PPARA (0.60) | PPARAPPARGKDM4E | |
| SCHEMBL1868848 | 0.89 | PPARA (0.59) | PPARAPPARGKDM4EPDE10A | |
| SCHEMBL1868386 | 0.89 | PPARA (0.57) | PPARAPPARGKDM4EALDH1A1LMNA | |
| SCHEMBL1871429 | 0.89 | PPARA (0.58) | PPARAPPARGKDM4E | |
| SCHEMBL1872814 | 0.88 | PPARA (0.58) | PPARAPPARGKDM4EALDH1A1LMNA | |
| SCHEMBL12802947 | 0.86 | PPARA (0.56) | PPARAPPARGKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483266-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-25 | — | — | EP | claimed |
| EP-2567957-A1 | Compounds for the treatment of dyslipidemia and related diseases | CADILA HEALTHCARE LIMITED (IN) | 2013-03-13 | — | — | EP | claimed |
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2012-10-04 | — | — | US | claimed |
| EP-2483266-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Cadila Healthcare Limited (IN) | 2012-08-08 | — | — | EP | claimed |
| WO-2011051961-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | claimed |
| EP-2483266-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-25 | — | — | EP | disclosed |
| EP-2567957-A1 | Compounds for the treatment of dyslipidemia and related diseases | CADILA HEALTHCARE LIMITED (IN) | 2013-03-13 | — | — | EP | disclosed |
| US-20120252896-A1 | METHODS AND COMPOSITIONS FOR MODULATION OF T-CELLS VIA THE KYNURENINE PATHWAY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-10-04 | — | — | US | disclosed |
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2012-10-04 | — | — | US | disclosed |
| EP-2483266-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Cadila Healthcare Limited (IN) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011051961-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | PCSK9, APOB, CPT1A | PPARA 132/4885PPARG 122/4885KDM4E 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.